Showing results (231-240 of 246) with videos related to

Sort By:
Pageof 25
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
ESMO Open|July 10, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners FoundationS Peters, M-L Meyer, F André, et al.
ESMO Open|May 16, 2025
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)A-S Hamy, B Grandal, F Jochum, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variantsM Messaoudene, T P Mourikis, J Michels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Pageof 25